

Clinical Microbiology and Infection

VOLUME 11, SUPPLEMENT 2, APRIL 2005

15th European Congress of Clinical Microbiology and Infectious Diseases Copenhagen, Denmark 2–5 April 2005

Page

1	Antibiotic sensitivity testing of anaerobic bacteria – Workshop arranged by ESGARAB
1	History of medical microbiology in Denmark
3	Update on toxoplasmosis (Symposium arranged with ESGT)
3	European guidelines for diagnosis of tick borne diseases (Symposium arranged with ESCAR)
4	Vancomycin- and methicillin-resistant <i>Staphylococcus aureus</i> (VMRSA): how to cope with it in the hospital setting? (Symposium arranged with ESGNI)
4	Management of relapses and outbreaks of <i>Clostridium difficile</i> (Symposium arranged with ESGCD)
5	Antibiotics for lower respiratory tract infections in primary care (Symposium arranged with ESPRIT)
6	Antibiotic use and policies: an in-depth look at ARPAC results (Symposium arranged with ESGAP)
6	Is the commensal anaerobic microflora involved in spreading antibiotic resistance? (Symposium arranged with ESGARAB)
7	Malaria control – what is in the pipeline?
8	<i>Pseudomonas aeruginosa</i> : a rogue bacterium in the intensive care unit (Symposium arranged with ESICM)
8	Tuberculosis: persistence and resistance
9	Clinical microbiology: what's new in conventional and molecular diagnostics? (Symposium arranged with ESGMD)
9	Antibiotic usage: practices and policy interventions
14	Hepatitis virus
17	From mild to severe respiratory tract infection: what's new with azalides? (Symposium arranged by PLIVA)
18	Emerging viral infections
20	Advances in febrile neutropenia
23	The impact of beta-lactamases on clinical practice
23	The year in HIV medicine
23	Coping with the severe acute respiratory syndrome
24	Advances in foreign body infections
24	Paediatric infections
26	New typing approaches for MRSA control
28	Pharmacokinetics and pharmacodynamics of antibiotics
30	Genetic typing for important viral infections: recent technological and conceptual developments (Symposium arranged with ESGEM)
31	Modifying the ribosome as a mechanism of resistance (Joint symposium arranged with ICAAC)
32	Patterns of antibiotic stewardship, use and resistance in European hospitals (Joint symposium arranged with ARPAC and ESAC)
33	Combination antifungal therapy (Symposium arranged with EFISG)
33	New diagnostic methods for the laboratory
38	Hospital infection: new sources and solutions

Contents

41	New antibacterials for the decade: strategies to deliver agents with novel actions (Symposium arranged by GlaxoSmithKline)
43	<i>Staphylococcus aureus</i> disease – from basic science to clinical practice
44	Benchmarking nosocomial infections (Symposium co-organised by SHEA and ESGNI)
44	Exotic infections
48	Emergence and molecular evolution of antibiotic resistance
52	Predictors of the clinical course of HIV infection and therapy
55	Antimicrobial growth promoters in food animal production
56	Crosstalk between bacterial pathogens and their host cells
56	Infection control: challenges now and ahead
56	<i>Burkholderia</i> , <i>Pseudomonas</i> and emerging infections in cystic fibrosis
57	Climate and environment: impact on infectious diseases
58	Crimean Congo haemorrhagic fever in south-eastern Europe
59	Computerised decision support for management of bacterial infections
59	Hepatitis C virus: new targets for drug and vaccine development and markers for therapy
60	Focus on <i>Mycobacterium tuberculosis</i>
62	Diagnosis and management of sepsis in the critically-ill patient (Symposium arranged with ISF)
62	MRSA – new challenges in hospital and community settings
66	Focus on extraction and amplification controls in molecular diagnostics
69	New developments in epidemiology of antibiotic resistance
73	Bacterial biofilms
74	Focus on new antibacterials
75	Emerging infections in the immuno-compromised host (Symposium arranged with EORTC/ IDSG)
76	Community-acquired MRSA in Europe – evolution at work
77	Recent trends in severe fungal infections
81	Antibiotic and antibiotic resistance mechanisms
85	Infections in the community: epidemiology, diagnosis and outcome
88	Metallo-beta-lactamases: a last frontier for beta-lactams?
89	Social-political consequences of the HIV pandemic: are we turning the tide?
89	Evolution and function of the haemagglutinin of the influenza virus
90	<i>Streptococcus pneumoniae</i> : a clonal war?
90	Recent advances in chlamydiology
92	Resistance to antifungal drugs
93	Emerging enteric pathogens: responding to the challenge
93	Influenza vaccination
94	New drugs to fight the resistance challenge
99	Metallo-beta-lactamases and resistance to carbapenems
106	Epidemiology of ESBL and MBL – I
114	Extended-spectrum beta-lactamase and other beta-lactamases
123	Various antimicrobial agents including disinfectants
127	Urinary tract infections
133	<i>Borrelia</i>
136	Antibiotic usage
143	Antibiotic policy intervention
148	Tuberculosis: diagnosis, resistance and immunology
159	<i>Brucella</i>
163	Toxoplasmosis
165	Clinical mycology
171	Clinical use of vaccines
174	Molecular methods for respiratory bacterial pathogens
182	Molecular methods for enteric pathogens
190	HIV
200	HCV: risk factors, diagnosis, clinical presentation and treatment
205	Bacteriology: role of selective media and identification systems
212	16S rRNA
216	Clinical mycology: case reports
221	Enterococci: epidemiology and resistance
230	Epidemiology of ESBL and MBL – II

238	Tigecycline, in vitro studies
246	Sexually transmitted diseases
253	Helicobacter
259	MRSA – virulence, genes, VISA and treatment
264	Training, scientific output in infectious disease
266	Pneumonia
271	Pharmacokinetics/pharmacodynamics of antibacterial drugs
280	Organ transplants
284	Exotic infections – I: case series
291	Infection and immunopathology
292	Staphylococcal infections
299	Mechanisms of resistance in staphylococci
302	Typing and epidemiology of MRSA
314	Antibiotic-resistant pneumococci and streptococci
326	Wound and fungal infections
328	Antibiotic resistance: nosocomial pathogens
334	Difficult to treat nosocomial infections
338	Susceptibility surveillance studies
341	Pharmacokinetics/pharmacodynamics of quinolones
346	Pharmacokinetics/pharmacodynamics of antifungals
350	Infection control: environmental and hand disinfection
354	Exotic infections – II
361	Fungal susceptibility testing
366	Skin and soft tissue infections
376	Fluroquinolones, in vitro studies
381	Antibacterial susceptibility studies – I
388	Mechanisms of resistance to macrolides
391	Paediatric infections
401	Mechanisms of antibiotic resistance in Gram-negative bacilli
408	Public health, surveillance and geographic information systems
411	Endocarditis
414	Enteric infection
423	Respiratory tract infection
435	Pneumococcal pneumonia
439	Pneumonia in non-HIV immunosuppressed patients
442	Detection of methicillin resistance
449	Infections and diagnosis in non-HIV immunosuppressed patients
456	Mechanisms of resistance to quinolones
461	Antibacterial susceptibility studies – II
469	Antibiotic-resistant community-acquired pathogens – I
478	Fungal diagnostics
483	ELISA-based diagnostics
486	<i>Clostridium difficile</i>
489	<i>Chlamydia trachomatis</i>
494	Hepatitis A, B and E viruses
499	Herpes virus
504	New drugs: in vitro studies
514	New drugs: in vivo studies
516	Pharmacokinetics/pharmacodynamics of anti-staphylococcal drugs
519	Infections in neutropenic patients
524	Procalcitonin, other markers of infection
527	Diagnosis of viral infections: new methods
531	Diagnosis of viral infections: respiratory and herpes viruses
536	Biofilms: pathogenesis and antibiotic susceptibility
546	CNS infections
551	Experimental CNS infections
554	Bloodstream infection
561	Catheter-related infections
563	Molecular bacteriology and mycology
569	Antifungal susceptibility studies

Contents

575	Pathogenesis of respiratory tract and other infections
583	Adverse drug reactions, probiotics
585	Antibiotic-resistant community-acquired pathogens – II
592	Pathogenesis of infections
597	Non-fermenter Gram-negative bacilli: epidemiology and resistance
609	Immunology, host defences, immunotherapy
616	Antibiotic resistance: nosocomial pathogens
622	Susceptibility testing methods
628	Surveillance of nosocomial infections
634	Environmental impact on nosocomial infections
636	Tuberculosis: clinical aspects and surveillance
648	Health care issues, public health, pharmaco-economics
651	New drugs
651	Pharmacokinetics, pharmacodynamics, drug interactions, tolerability
654	In vitro activity of antimicrobial agents
659	Mechanisms of action and of resistance of antimicrobial drugs
661	Epidemiology of resistance, antibiotic usage
667	Community-acquired infections
673	Nosocomial infections, infection control
685	Infection in the immunocompromised host (except HIV)
692	Immunology, host defenses, immunotherapy
695	Pathogenesis, animal models including experimental treatment
697	Molecular bacteriology (incl. diagnostics)
699	Diagnostic methods (other than molecular)
706	Mycobacterial infections (incl. diagnostics)
710	Fungal infections
718	Tropical and parasitic diseases
720	Sexually transmitted diseases (except HIV)
722	Molecular virology (incl. diagnostics)
724	Viral diseases (not HIV, Herpes, Hepatitis)
725	AIDS and HIV infection
730	Hepatitis
734	Herpes virus
737	Emerging infectious diseases
739	Vaccines
742	Infection in transplant recipients
742	Paediatric infections
745	Author index
771	Subject index